Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.00 and traded as high as $0.0004. Syros Pharmaceuticals shares last traded at $0.0004, with a volume of 4,364 shares.
Syros Pharmaceuticals Price Performance
The stock has a market capitalization of $2,683.20, a P/E ratio of -0.00 and a beta of 1.31.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, that is pioneering a new class of targeted therapeutics by focusing on the control of gene expression. Founded in 2015 as a spin-out from the Broad Institute, Syros leverages its proprietary gene control platform to identify and drug key noncoding regions of the genome that regulate disease-driving genes. The company’s approach aims to convert previously undruggable gene targets into precise medicines for patients with cancer and rare genetic disorders.
Syros’ lead development candidate, tamibarotene (SY-1425), is an oral, selective RARα agonist being evaluated in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) characterized by RARA dependence.
Recommended Stories
- Five stocks we like better than Syros Pharmaceuticals
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
